The findings, published in JAMA Cardiology, confirm that dapagliflozin is a safe, effective treatment option for patients with heart failure with reduced ejection fraction.
“Value can be defined as delivered care divided by cost,” the specialists wrote. “Ideally, each patient receives the same good quality of care in an equitable, timely way.”
One important detail, however, was that acute kidney injury was more common for kidney transplant recipients. The researchers listed numerous potential explanations for this trend.
The analysis, published in the Journal of the American College of Cardiology, tracked nearly 1,000 patients treated for their first myocardial infarction from November 1995 to October 1997.